Perth-based Elevate Uranium (ASX: EL8) has appointed experienced uranium geologist Dr Andy Wilde to the role of exploration manager in charge of a strong portfolio of uranium assets across Australia and Namibia.
Dr Wilde’s career in exploration and research has spanned over 35 years and included senior roles at Paladin Energy (ASX: PDN), Deep Yellow (ASX: DYL), 92 Energy (ASX: 92E), BHP Minerals (ASX: BHP), Birimian and Gold Fields Australia.
These roles took him to West Africa, Bolivia, China, Democratic Republic of Congo, Mongolia, Canada and Russia in the search for uranium, gold, lithium, base metals, coil, and oil and gas.
Dr Wilde is a graduate of the Australian Institute of Company Directors and a current board member for the Australian Institute of Geoscientists (having previously held the positions of vice president and secretary).
He is a registered professional geoscientist and fellow of the Australian Institute of Geoscientists, and a chartered professional and fellow of the Australian Institute of Mining and Metallurgy.
He has consulted to the United Nations International Atomic Energy Agency and is an adjunct senior research fellow at the University of Western Australia’s Centre for Exploration Targeting.
Dr Wilde’s skill set includes: exploration strategic planning and management; assessment of exploration and resource projects; due diligence studies; exploration targeting; geometallurgy and interpretation of geochemical surveys; and geoscience research.
Over the past decade, he has predominantly worked in Namibia, Canada and Australia and gained a considerable understanding and knowledge of calcrete-hosted mineralisation contained within palaeochannels, which is the same geological setting as the majority of Elevate’s exploration assets.
Elevate managing director Murray Hill said Dr Wilde will be a good fit for Elevate.
“Andy is one of a select group of geologists who have relevant experience in surficial calcrete-hosted uranium mineralisation contained within paleochannels such as we have in Namibia [and] an intimate knowledge of our Australian assets having previously worked on the vast majority of these with other companies,” he said.
“We are delighted that he has joined our team and believe his knowledge and experience will add substantial value to our suite of assets.”
Dr Wilde said there is much value to derive from managing Elevate’s exploration assets.
“Over recent years, I have observed with interest [the] counter-cyclical strategy to acquire uranium assets in Namibia and Australia,” he said.
“I am excited by the exploration potential of these assets and their location in two of the most prospective uranium jurisdictions in the world, in geological settings and countries that I know very well.”
Dr Wilde commences his new role this week.